表紙
市場調査レポート

移行上皮癌 (尿路上皮細胞癌) - パイプライン分析

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015

発行 Global Markets Direct 商品コード 257816
出版日 ページ情報 英文 168 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
移行上皮癌 (尿路上皮細胞癌) - パイプライン分析 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015
出版日: 2015年06月30日 ページ情報: 英文 168 Pages
概要

移行上皮癌は、尿管あるいは腎孟の移行細胞(膀胱の内側)で発生します。 症侯は、血尿、背中の痛み、疲労感、排尿時の痛み、頻尿、原因不明の体重の減少などがあります。素因としては年齢、喫煙、特定化学物質への暴露、慢性的な膀胱炎などが挙げられます。 治療は、化学療法や放射線治療があります。

当レポートでは、 移行上皮癌 (尿路上皮細胞癌)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 移行上皮癌 (尿路上皮細胞癌) 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Amgen Inc.
  • Sanofi
  • 第一三共
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Dendreon Corporation
  • Cadila Pharmaceuticals Ltd.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • cabazitaxel
  • tigatuzumab
  • trebananib
  • CADI-05
  • lapuleucel-t
  • dovitinib lactate
  • PF-03446962
  • Vaccine Targeting NY-ESO-1 for Oncology
  • CEP-11981

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6814IDB

Summary

Global Markets Direct's, 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015', provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview
  • Therapeutics Development
    • Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Overview
    • Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Development by Companies
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Development by Companies
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Companies Involved in Therapeutics Development
    • Altor BioScience Corporation
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • ATLAB Pharma SAS
    • BIND Therapeutics, Inc.
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • Eli Lilly and Company
    • Exelixis, Inc.
    • Incyte Corporation
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Mirati Therapeutics Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Teva Pharmaceutical Industries Limited
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AdIL-24 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALT-801 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMG-228 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • amrubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATL-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-4547 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • B-701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBI-503 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEP-11981 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enfortumab vedotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epacadostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-42756493 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mitomycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mocetinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ramucirumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-408701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vandetanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Recent Pipeline Updates
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Product Development Milestones
    • Featured News & Press Releases
      • May 13, 2015: Mirati Therapeutics to Provide Updates on Mocetinostat at 2015 ASCO Annual Meeting
      • May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015
  • Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Development by Companies, H1 2015 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Development by Companies, H1 2015 (Contd..1)
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Altor BioScience Corporation, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Amgen Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Astellas Pharma Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by AstraZeneca Plc, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by ATLAB Pharma SAS, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by BIND Therapeutics, Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boehringer Ingelheim GmbH, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boston Biomedical, Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Eli Lilly and Company, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Exelixis, Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Incyte Corporation, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Johnson & Johnson, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Merck & Co., Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Mirati Therapeutics Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Novartis AG, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Pfizer Inc., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sanofi, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Recent Pipeline Updates, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects, H1 2015
  • Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015
  • Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top